Antibiotic distribution and recovery in tissue
Project factsheets
The Innovative Health Initiative builds on the successes of the Innovative Medicines Initiative (IMI), which launched over 180 projects. Many IMI projects are still ongoing and are monitored by the IHI Programme Office. This section features the factsheets of all IMI projects. Once IHI projects are up and running, we will also promote them here.
Displaying 20 projects/programmes
Antimicrobial Resistance Accelerator
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections
Combatting bacterial resistance in Europe - molecules against Gram negative infections
Combatting Bacterial Resistance in Europe
Collaboration for prevention and treatment of MDR bacterial infections
Driving re-investment in R&D and responsible antibiotic use
European Gram-negative Antibacterial Engine
European regimen accelerator for tuberculosis
Novel Gram-negative antibiotic now
Inhaled antibiotics in bronchiectasis and cystic fibrosis
New Drugs for Bad Bugs
Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Molecular basis of the bacterial cell wall permeability
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments
Academia and industry united innovation and treatment for tuberculosis
The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
